Generic Maxalt gets tentative OK
The U.S. Food and Drug Administration has granted tentative approval for Teva Pharmaceuticals' generic form of the migraine medicine Maxalt. Final approval of the generic, rizatriptan benzoate, is anticipated upon expiration of patent protection for the brand name drug in June 2012.
(Medical News Today) UPDATED 04/21/2008Click here to read the full story

